Cencora, Inc. $COR Holdings Decreased by Close Asset Management Ltd

Close Asset Management Ltd cut its holdings in Cencora, Inc. (NYSE:COR) by 73.4% in the 3rd quarter, HoldingsChannel reports. The institutional investor owned 117,778 shares of the company’s stock after selling 325,162 shares during the period. Cencora makes up about 0.8% of Close Asset Management Ltd’s portfolio, making the stock its 29th largest holding. Close Asset Management Ltd’s holdings in Cencora were worth $36,799,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cornerstone Wealth Group LLC grew its holdings in shares of Cencora by 1.3% during the third quarter. Cornerstone Wealth Group LLC now owns 2,383 shares of the company’s stock valued at $745,000 after purchasing an additional 30 shares during the last quarter. Security Financial Services INC. boosted its position in Cencora by 2.6% during the 3rd quarter. Security Financial Services INC. now owns 1,325 shares of the company’s stock valued at $414,000 after purchasing an additional 33 shares during the period. Hemington Wealth Management grew its stake in Cencora by 12.0% during the 3rd quarter. Hemington Wealth Management now owns 327 shares of the company’s stock worth $102,000 after buying an additional 35 shares during the last quarter. Quadcap Wealth Management LLC increased its position in Cencora by 1.5% in the second quarter. Quadcap Wealth Management LLC now owns 2,409 shares of the company’s stock worth $722,000 after buying an additional 36 shares during the period. Finally, Howard Capital Management Inc. lifted its stake in Cencora by 2.5% in the third quarter. Howard Capital Management Inc. now owns 1,499 shares of the company’s stock valued at $468,000 after buying an additional 37 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the sale, the executive vice president owned 18,796 shares of the company’s stock, valued at $6,484,620. This trade represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 15,220 shares of company stock valued at $5,282,867 in the last quarter. Insiders own 0.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the stock. Jefferies Financial Group upgraded shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Robert W. Baird set a $415.00 price target on shares of Cencora in a research note on Tuesday, January 13th. TD Cowen lifted their price target on Cencora from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, November 10th. Mizuho increased their price objective on Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, UBS Group raised their target price on Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $399.00.

Cencora Price Performance

Shares of NYSE:COR opened at $366.60 on Friday. The stock has a market cap of $71.31 billion, a price-to-earnings ratio of 44.06, a PEG ratio of 1.69 and a beta of 0.68. The company has a debt-to-equity ratio of 3.62, a current ratio of 0.92 and a quick ratio of 0.51. Cencora, Inc. has a 12 month low of $248.11 and a 12 month high of $377.54. The stock’s 50 day moving average price is $351.11 and its 200 day moving average price is $333.02.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to analysts’ expectations of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same period last year, the firm earned $3.73 EPS. Equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Stockholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. Cencora’s dividend payout ratio (DPR) is 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.